Search research articles
Contact Us
Filters
Showing results (121-130 of 168) with videos related to
Page
of 17
Sort By:
Nature Medicine
|
July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Investigational New Drugs
|
June 28, 2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Antoine Italiano, Wilson H Miller, Jean-Yves Blay, et al.
Matrix Biology : Journal of the International Society for Matrix Biology
|
July 16, 2022
Phosphorylation of eIF4E in the stroma drives the production and spatial organisation of collagen type I in the mammary gland
Samuel E J Preston, Margarita Bartish, Vincent R Richard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2013
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors
Antonio Jimeno, Glen J Weiss, Wilson H Miller, et al.
Investigational New Drugs
|
February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Autophagy
|
June 2, 2021
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance
Michael S Dahabieh, Fan Huang, Christophe Goncalves, et al.
Blood
|
May 23, 2008
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Guillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, et al.
Nature Cancer
|
February 20, 2025
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial
Aurelien Marabelle, David M O'Malley, Andrew E Hendifar, et al.
Nature
|
May 30, 2014
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation
Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Sarit Assouline, et al.
Journal for Immunotherapy of Cancer
|
April 23, 2015
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin, Arkadiusz Z Dudek, Theodore F Logan, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 168) with videos related to
Sort By:
Page
of 17
Nature Medicine
|
July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Investigational New Drugs
|
June 28, 2021
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors
Antoine Italiano, Wilson H Miller, Jean-Yves Blay, et al.
Matrix Biology : Journal of the International Society for Matrix Biology
|
July 16, 2022
Phosphorylation of eIF4E in the stroma drives the production and spatial organisation of collagen type I in the mammary gland
Samuel E J Preston, Margarita Bartish, Vincent R Richard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 12, 2013
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors
Antonio Jimeno, Glen J Weiss, Wilson H Miller, et al.
Investigational New Drugs
|
February 7, 2024
CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
Andrew J Armstrong, Ravit Geva, Hyun Cheol Chung, et al.
Autophagy
|
June 2, 2021
Silencing PEX26 as an unconventional mode to kill drug-resistant cancer cells and forestall drug resistance
Michael S Dahabieh, Fan Huang, Christophe Goncalves, et al.
Blood
|
May 23, 2008
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Guillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, et al.
Nature Cancer
|
February 20, 2025
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial
Aurelien Marabelle, David M O'Malley, Andrew E Hendifar, et al.
Nature
|
May 30, 2014
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation
Hiba Ahmad Zahreddine, Biljana Culjkovic-Kraljacic, Sarit Assouline, et al.
Journal for Immunotherapy of Cancer
|
April 23, 2015
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Asim Amin, Arkadiusz Z Dudek, Theodore F Logan, et al.
Page
of 17